Toll-Like Receptor 4 Polymorphisms and Risk of Gram-Negative Bacteremia after Allogeneic Stem Cell Transplantation. A Prospective Pilot Study
Received 16 September 2008; accepted 17 April 2009. published online 29 June 2009.
Refers to erratum:
Erratum
, 25 September 2009 Biology of Blood and Marrow Transplantation
January 2010 (Vol. 16, Issue 1, Page 128) Full Text |
Full-Text PDF (50 KB)
The Toll-like receptor 4 (TLR4) gene is a major recognition receptor for lipopolysaccharide (LPS). In a pilot prospective study, we examined the association of 2 TLR4 polymorphisms (Asp299Gly and Thr399Ile) in the donor or the recipient with Gram-negative bloodstream infection (BSI) in 77 allogeneic hematopoietic stem cell transplant (HSCT) patients. Heterozygosity at both loci was defined as “risk genotype.” The cumulative incidence of infection was estimated by treating death prior to infection as a competing risk event and compared between relevant groups using a modified chi-square test. Nine patients had the risk genotype based on donor and 5 based on recipient genotype data. Donor risk genotype showed marginal statistical significance (0.06) in univariate analysis, but not in multivariate analysis. A larger study is required to validate our findings and define genetic susceptibility to this serious infection in HSTC patients.
1Department of Medicine, Service of Infectious Disease, Memorial Sloan-Kettering Cancer Center, New York, New York
2Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York
3Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
4Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
Correspondence and reprint requests to: Genovefa A. Papanicolaou, MD, Department of Medicine, Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box, 9, New York, NY 10021.
Present address: FIRC Institute of Molecular Oncology, Milan, Italy.
Financial disclosure: See Acknowledgments on page 1133.